https://www.selleckchem.com/pr....oducts/vps34-inhibit
generation as well as higher levels of the proinflammatory cytokines IL-2 and TNFα in serum. We conclude that the key regulator of MHCII expression, Mhc2ta, modulates neuroinflammation, αsyn-seeded Lewy-like pathology, dopaminergic neurodegeneration and motor impairment. This makes Mhc2ta and microglial antigen presentation promising therapeutic targets for reducing the progressive neuropathology and clinical manifestations in PD. We conclude that the key regulator of MHCII expression, Mhc2ta, modulates neuroinflammation, αsyn
Like
Comment
Share
